logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5183.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5183.produseast1
Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)-based regimens for rifampicin-resistant tuberculosis in non-trial settings - A prospective cohort study in Belarus and Uzbekistan

Sinha A, Klebe R, Rekart ML, Alvarez JL, Skrahina A,  et al.
2025-02-18 • Clinical Infectious Diseases
2025-02-18 • Clinical Infectious Diseases

BACKGROUND

Only 63% of patients initiating multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment in 2020 were treated successfully. 24-Wee...

Journal Article
|
Research

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M,  et al.
2025-02-01 • Lancet Global Health
2025-02-01 • Lancet Global Health

BACKGROUND

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...

Journal Article
|
Research

Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan

Moe S, Azamat I, Allamuratova S, Oluya M, Khristusev A,  et al.
2024-09-01 • IJTLD OPEN
2024-09-01 • IJTLD OPEN

BACKGROUND

Dru...

Journal Article
|
Research

Yield of TB screening in prisons in Tajikistan

Moe S, Asozoda M, Aung A, Dusmatova Z, Akintore F,  et al.
2024-08-01 • IJTLD OPEN
2024-08-01 • IJTLD OPEN

BACKGROUND

The rate of TB in prison institutions is estimated to be 23 times higher than in the general population. Limited documentation exists regarding TB screening in Tajiki...

Journal Article
|
Research

A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020

Rekart M, Thit P, Oluya M, Moe S, Hasan T,  et al.
2024-07-01 • IJTLD OPEN
2024-07-01 • IJTLD OPEN

Background

Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The...

Journal Article
|
Research

Primary bedaquiline resistance in Karakalpakstan, Uzbekistan

Moe S, Rekart ML, Hernandez D, Sholpan A, Ismailov A,  et al.
2023-05-01 • International Journal of Tuberculosis and Lung Disease
2023-05-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND:
Bedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB (RR-TB). However, resistance to BDQ is now emerging. There are no standardised regimens for ...